Trial reportNutrients2020
A Partly Fermented Infant Formula with Postbiotics Including 3'-GL, Specific Oligosaccharides, 2'-FL, and Milk Fat Supports Adequate Growth, Is Safe and Well-Tolerated in Healthy Term Infants: A Double-Blind, Randomised, Controlled, Multi-Country Trial.
Trial report in Nutrients, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Safety and efficacy of adding postbiotics in infant formula: a systematic review and meta-analysis.Pediatric research · 2024Pooled it
- Clinical Studies on the Supplementation of Manufactured Human Milk Oligosaccharides: A Systematic Review.Nutrients · 2023Pooled it
- The Association of Formula Protein Content and Growth in Early Infancy: A Systematic Review and Meta-Analysis.Nutrients · 2022Pooled it
- Trial
- 2'-FL's Depiction of the Human Physiological Function Landscape.Food science & nutrition · 2026Review
- Postbiotics: An Overview and Recommendations for Improved Reporting.Molecular nutrition & food research · 2026Review
- Limited Evidence of Benefits from Clinical Trials of Human-Identical Milk Oligosaccharides for Infants.Advances in nutrition (Bethesda, Md.) · 2026Review
- Postbiotic Effect of Escherichia coli CEC15 and Escherichia coli Nissle 1917 on a Murine Model of 5-FU-induced Intestinal Mucositis.Probiotics and antimicrobial proteins · 2025Article
- Emerging Nonthermal Technologies for the Production of Postbiotics.Comprehensive reviews in food science and food safety · 2025Review
- Yogurt in Combination with InactivatedAnimals : an open access journal from MDPI · 2025Article
- Growth and gastrointestinal tolerance of healthy formula-fed infants: a multicentre, prospective observational study.BMC pediatrics · 2025Observational
- Clinical evidence and mechanistic pathways of human milk oligosaccharide supplementation for health benefits: an updated review.Frontiers in nutrition · 2025Review
- Respiratory diseases and the gut microbiota: an updated review.Frontiers in cellular and infection microbiology · 2025Review
- Health Benefits and Safety of Postbiotics Derived from Different Probiotic Species.Current pharmaceutical design · 2025Review
- Human Milk Oligosaccharides: Decoding Their Structural Variability, Health Benefits, and the Evolution of Infant Nutrition.Nutrients · 2024Review
- Postbiotics are a candidate for new functional foods.Food chemistry: X · 2024Review
- A Comprehensive Overview of Postbiotics with a Special Focus on Discovery Techniques and Clinical Applications.Foods (Basel, Switzerland) · 2024Review
- Analysis of the Fecal Metabolomic Profile in Breast vs. Different Formula Milk Feeding in Late Preterm Infants.Metabolites · 2024Article
- Can Postbiotics Represent a New Strategy for NEC?Advances in experimental medicine and biology · 2024Review
- Lactational and geographical variation in the concentration of six oligosaccharides in Chinese breast milk: a multicenter study over 13 months postpartum.Frontiers in nutrition · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 5 countries.
Funding
Abstract
This study investigated growth, safety, and tolerance in healthy infants consuming a partly fermented infant formula (IF) with postbiotics, 2'-linked fucosyllactose (2'-FL), a specific prebiotic mixture of short-chain galacto-oligosaccharides (scGOS) and long-chain fructo-oligosaccharides (lcFOS), and milk fat. This double-blind, controlled trial randomised 215 fully IF-fed infants ≤ 14 days of age to either: Test Group (IF) containing 26% fermented formula with postbiotics derived from Lactofidus fermentation process (including 3'-Galactosyllactose; 3'-GL), 0.8 g/100 mL scGOS/lcFOS (9:1), 0.1 g/100 mL 2'-FL, and milk fat), or Control group (IF with 0.8 g/100 mL scGOS/lcFOS (9:1)) until 17 weeks of age. Fully breastfed infants were included as a reference. Anthropometric measures, gastrointestinal symptoms, and safety were assessed monthly. Equivalence in weight gain (primary outcome) between the Test and Control groups was confirmed (difference in means -0.08 g/day; 90% CI (-1.47;1.31)) with estimated mean weight gain (SE) of 31.00 (0.59) g/day and 31.08 (0.60) g/day, respectively, (PP population,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.